New scan could predict rectal cancer treatment success early

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) 0 to 2 * Histologically proven rectal cancer * clinical tumor classification (cT) : cT3 - cT4 or all T / N+ / M0 * Tumor resectable or considered resectable after chemoradiotherapy * Decision chemotherapy followed by neoadjuvant chemoradiotherapy decided at the organ Multidisciplinary Meeting * Absence of distant metastases * Adequate contraception for women of childbearing potential * Free, signed and informed consent * For women of childbearing potential : negative pregnancy test Exclusion Criteria: * Subject with Uncontrolled diabetes * Contraindication to surgery * Contraindication to MRI * Contraindication to PET scan * Contraindication to chemotherapy * History of pelvic radiotherapy * History of major co-morbidity that may prevent treatment and no active infection (HIV or chronic hepatitis B or C) * Colloid (mucinous) adenocarcinoma * Presence of distant metastases * Contraindication to 5-FluoroUracil (FU), oxaliplatin or irinotecan * History of known Gilbert's disease * Patient with known UGT1A1 genotype * Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency * Medical history of chronic diarrhea or inflammatory disease of the colon or rectum * Medical history of angina or myocardial infarction. * Active progressive infection or any other serious medical condition that could compromise the administration of the treatment * Other concurrent cancer, or medical history of cancer other than treated in situ cervical carcinoma or basal cell carcinoma or squamous cell carcinoma * Patient enrolled in another clinical trial testing an investigational agent * Pregnant or breastfeeding woman * Persons deprived of their freedom or under guardianship or incapable of giving consent * Any psychological, familial, sociological or geographic condition that may interfere with the study protocol or follow-up schedule